Investigational drug · Phase 2
DOC1021
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma (GBM), Refractory Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "DOC1021"
First trial start
2025
Mar 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DOC1021", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma (GBM)
- Refractory Melanoma
Approved drugs for the same conditions: Melanoma · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DOC1021" as an intervention, largest first.
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)Pivotal-lookingRecruiting
Diakonos Oncology CorporationIndustry
NCT06805305 · 180 participants (planned) · Start Mar 17, 2025 · Primary completion Mar 2030
Drug: DOC1021; Temodar (Temozolomide) · For: Glioblastoma (GBM)
Sites: Gilbert, Arizona; Duarte, California; Newport Beach, California · 18 sites in all
Diakonos Oncology CorporationIndustry
NCT07288112 · 35 participants (planned) · Start Apr 6, 2026 · Primary completion Jan 2031
Drug: DOC1021; pIFN (peginterferon alfa-2a) · For: Refractory Melanoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Scottsdale, Arizona · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.
Georges JF, Clay C, Amin S, et al. · medRxiv 2026
Also in development for Glioblastoma (GBM)
- BreakVaxPhase 22 trials
BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
- silevertinibBDTX-1535Phase 22 trials
Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM
- JBI-778Phase 21 trial
Jubilant Therapeutics Inc. · Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG)
- TGX-007Phase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
- ValaciclovirPhase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.